Therefore, there is a need to design more selective ACE inhibitors that preferentially target either nACE or cACE for the treatment of inflammation, fibrosis, postmyocardial infarction and hypertension, which would be associated with fewer side effects. This evidence concerns the gene ACE and Hypertension.